Press Release|Articles|December 3, 2024
Camber Pharmaceuticals Announces Addition of Decitabine for Injection
Listen
0:00 / 0:00
Key Takeaways
- Decitabine for Injection targets adult patients with myelodysplastic syndromes, including various subtypes and chronic myelomonocytic leukemia.
- The product is offered in a 50 mg single-dose vial, enhancing treatment accessibility.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Decitabine for Injection.
Decitabine for Injection is indicated for treatment of:
- adult patients with myelodysplastic syndromes (MDS)
- de novo and secondary MDS of all French-American British subtypes
- refractory anemia with excess blasts
- chronic myelomonocytic leukemia
Decitabine for Injection is available in a 50 mg Single-Dose Vial.
To find out more information on Decitabine for Injection please visit:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Two Weeks In: What the Medicare GLP-1 Bridge Actually Looks Like at the Counter
2
Lilly Prepares for Retatrutide FDA Filing Following Additional Phase 3 Data in Diabetes, CVD
3
Combating the Decline in Influenza Vaccination Rates: A Pharmacist’s Perspective
4
US Obesity Hits 41% in Adults, 20% in Youth Over 24-Year Period
5